Theravance Biopharma (TBPH) investor relations material

Executive summary

• Achieved record non-GAAP profitability for the second consecutive quarter in Q4 2025, driven by strong YUPELRI performance and milestone payments from YUPELRI and TRELEGY sales.

• Organizational restructuring underway, including a 50% workforce reduction and wind-down of R&D, following the Phase 3 CYPRESS study results.

• Strategic Review Committee is actively evaluating value-maximizing alternatives, including a potential sale.

Financial highlights

• Q4 2025 revenue was $45.9 million, including $20.9 million from Viatris collaboration and $25 million in YUPELRI milestone revenue.

• Net income for Q4 2025 was $61.0 million, compared to a net loss of $15.5 million in Q4 2024, benefiting from $75 million in milestone payments.

• Full-year 2025 YUPELRI net sales reached $266.6 million, up 12% year-over-year; TRELEGY global net sales were $3.9 billion, up 12% year-over-year.

• Cash, cash equivalents, and marketable securities totaled $326.5 million at year-end 2025; expected to reach ~$400 million by end of Q1 2026 with no debt.

Outlook and guidance

• Restructuring expected to reduce operating expenses by ~60% and generate $60–$70 million in annualized cash flow starting Q3 2026.

• Full benefit of cost savings to be realized by Q3 2026; guidance excludes potential $100 million TRELEGY milestone in 2026.